Neonatal Phase 1 Valacyclovir Study
- Registration Number
- NCT05468619
- Brief Summary
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration. If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. The dose that these subjects will receive will be predicated upon the pharmacokinetic data from Cohort 1.
- Detailed Description
A Phase 1, open label multicenter trial to assess the safety and pharmacokinetics (PKs) of oral valacyclovir in neonates who are at risk of acquiring neonatal herpes simplex virus disease. This study will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates whose mothers have a history of genital HSV infection and received oral valacyclovir in the last several weeks of pregnancy, as per the recommendations of the American College of Obstetrics and Gynecology (ACOG) (9), will be eligible for enrollment. Cohort 1 will be comprised of eight subjects. Following informed consent, each subject will receive 10 mg/kg of oral valacyclovir, and may start taking oral valacyclovir while still in the birth hospital, with subsequent dosing at home, or may start taking oral valacyclovir following discharge from the birth hospital. If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. The dose that these subjects will receive will be predicated upon the pharmacokinetic data from Cohort 1. The primary study objective is to establish the dose of valacyclovir in neonates that reliably achieves systemic acyclovir exposures comparable to 10 mg/kg of parenterally administered acyclovir. The secondary study objectives are: 1) to define the pharmacokinetic profile of acyclovir in neonates receiving oral valacyclovir and 2) to assess and describe the safety profile of valacyclovir among treated neonates.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 16
-
Signed informed consent from parent(s) or legal guardian(s)
-
Maternal history of genital HSV infection
-
Maternal receipt of oral acyclovir, valacyclovir, or famciclovir suppressive therapy for = 7 days prior to delivery
-
Gestational age = 38 weeks at birth
-
= 2 days of age at study enrollment*
-
Weight at study enrollment = 2,000 grams
- For purposes of this study, the calendar day of birth is Day of Life 0
- Evidence of neonatal HSV infection
- Evidence of sepsis
- Known renal anomalies or dysfunction
- Maternal genital lesions suspicious for HSV at the time of delivery
- Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry)
- Current receipt in the neonate of acyclovir, ganciclovir, famciclovir, or any investigational drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cohort 2 Valacyclovir If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. If the mean of observed acyclovir exposures of subjects in Cohort 1 are below 24,000 ngxhr/mL, AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose of 20 mg/kg administered two times daily for 5 days. Alternatively, if the mean of observed acyclovir exposures of subjects in Cohort 1 are above 48,000 ngxhr/mL AND if no Grade 3 or Grade 4 AEs or SAEs are detected in any of the study subjects, then the 8 subjects enrolled in Cohort 2 will receive oral valacyclovir at a dose that has been linearly adjusted downward to target 36,000 ngxh/mL area-under-the-concentration-time curve from 0 to 12 hours (AUC12). Cohort 1 Valacyclovir A cohort of neonates who are at risk of acquiring neonatal herpes simplex virus disease will receive 10 mg/kg of valacyclovir will be administered orally two times daily for 5 days. N=8
- Primary Outcome Measures
Name Time Method Neonatal plasma acyclovir mean AUC12 concentrations Days 1 - 5 To establish the dose of valacyclovir in neonates that reliably achieves systemic acyclovir exposures comparable to 10 mg/kg of parenterally administered acyclovir. Acyclovir target concentration of following oral valacyclovir dosing is 24,000 ngxhr/mL to 48,000 ngxhr/mL.
- Secondary Outcome Measures
Name Time Method Half-life (t1/2) of acyclovir Days 1 - 5 To define the pharmacokinetic profile of acyclovir in neonates receiving oral valacyclovir
Occurrence of Grade 3 Adverse Events (AEs) Days 1 - 42 To assess and describe the safety profile of valacyclovir among treated neonates
Maximum Serum Concentration (Cmax) of acyclovir Days 1 - 5 To define the pharmacokinetic profile of acyclovir in neonates receiving oral valacyclovir
Occurrence of Grade 4 Adverse Events and Serious Adverse Events Days 1 - 42 To assess and describe the safety profile of valacyclovir among treated neonates
Oral Clearance (CL/F) of acyclovir Days 1 - 5 To define the pharmacokinetic profile of acyclovir in neonates receiving oral valacyclovir
Time to the maximum concentration (Tmax) of acyclovir Days 1 - 5 To define the pharmacokinetic profile of acyclovir in neonates receiving oral valacyclovir
Volume of distribution (V/F) of acyclovir Days 1 - 5 To define the pharmacokinetic profile of acyclovir in neonates receiving oral valacyclovir
Trial Locations
- Locations (12)
Nationwide Children's Hospital - Infectious Diseases
🇺🇸Columbus, Ohio, United States
Children's of Alabama Child Health Research Unit (CHRU)
🇺🇸Birmingham, Alabama, United States
Emory University School of Medicine
🇺🇸Atlanta, Georgia, United States
University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases
🇺🇸Louisville, Kentucky, United States
M Health Fairview Masonic Children's Hospital
🇺🇸Minneapolis, Minnesota, United States
Washington University in St. Louis
🇺🇸Saint Louis, Missouri, United States
University of Nebraska Medical Center - Children's Hospital and Medical Center - Infectious Diseases
🇺🇸Omaha, Nebraska, United States
Steven and Alexandra Cohen Childrens Medical Center of New York - New Hyde Park - Infectious Disease
🇺🇸Queens, New York, United States
University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases
🇺🇸Rochester, New York, United States
SUNY Upstate Medical University Hospital - Pediatrics
🇺🇸Syracuse, New York, United States
Atrium Health ID Consultants & Infusion Care Specialists
🇺🇸Charlotte, North Carolina, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States